Novel cancer stem cell killing agent for gastric cancer and application thereof

• Main Authors: LI JINGDUAN, CHEN TIE, CHEN JIAJIE, CHANG GANG, SHU XINGSHENG, LI CHENYANG, WANG SHAOXIANG
• Format: Patent
• Language: Chinese; English
• Published: 18.01.2019
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention discloses a novel application of a lipid-lowering drug Evacetrapib in the treatment of gastric cancer tumor stem cells. Using gastric cancer stem cells as a model, we found that Evacetrapib could not only inhibit the growth of gastric cancer cell line, but also promote its apoptosis. It can also inhibit the growth of gastric cancer stem cells and promote their apoptosis. The resultsshowed that Evacetrapib significantly inhibited the growth of transplanted tumor derived from gastric cancer stem cells. Western blot analysis showed that apoptosis-associated protein C-PARP The expression of increased in a concentration-dependent manner and the activation of STAT3 phosphorylation decreased in a concentration-dependent manner. The mechanism of Evacetrapib in the treatment of gastric cancer stem cells may be related to the inhibition of phosphorylation of STAT3. Therefore, Evacetrapib can be used as a new therapeutic drug for gastric cancer stem cells. 本发明公开了降脂药Evacetrapib在胃癌肿瘤干细胞治疗中的新应用。以胃癌肿瘤干细胞为模型，我们